Potential predictors of long-term survival after surgery for patients with stage IV colorectal cancer

Anticancer Research

Volumn 26, Issue 2 B, 2006, Pages 1377-1383

  Hotta, Tsukasa ^a   Takifuji, Katsunari ^a   Arii, Kazuo ^a   Yokoyama, Shozo ^a   Matsuda, Kenji ^a   Higashiguchi, Takashi ^a   Tominaga, Toshiji ^a   Oku, Yoshimasa ^a   Yamaue, Hiroki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Colorectal cancer stage IV; CPT 11; l LV 5FU

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; UFT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERBILIRUBINEMIA; KAPLAN MEIER METHOD; LEUKOPENIA; LIVER RESECTION; LONG TERM CARE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; UNIVARIATE ANALYSIS; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HEPATECTOMY; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TEGAFUR; URACIL;

EID: 33645829304     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Le Voyer TE, Sigurdson ER, Hanlon AL et al: Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 21: 2912-2919, 2003.
2. Yamaue H, Tanimura H, Kono N et al: Clinical efficacy of doxifluridine and correlation to in vitro sensitivity of anticancer drugs in patients with colorectal cancer. Anticancer Res 23: 2559-2564, 2003.
3. Dhar DK, Yoshimura H, Kinukawa N et al: Metastatic lymph node size and colorectal cancer prognosis. J Am Coll Surg 200: 20-28, 2005.
4. Walker J and Quirke P: Prognosis and response to therapy in colorectal cancer. Eur J Cancer 38: 880-886, 2002.
5. Francini G, Petrioli R, Lorenzini L et al: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterol 106: 899-906, 1994.
6. Evans RM, Laskin JD and Hakala MT: Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41: 3288-3295, 1981.
7. Petrelli N, Douglass HO, Herrera L et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7: 1419-1426, 1989.
8. Petrelli N, Herrera L, Rustum Y et al: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5: 1559-1565, 1987.
9. Wolmark N, Rockette H, Fisher B et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11: 1879-1887, 1993.
10. Zhang ZG and Rustum YM: Pharmacologic rationale for fluoropyrimidine- leucovorin combination: biochemical mechanisms. Semin Oncol 19: 46-50, 1992.
11. Cunningham D, Pyrhönen S, James RD et al: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 552: 1413-1418, 1998.
12. UICC: TNM Classification of Malignant Tumors. 4th Ed. Berlin Heidelberg, New York: Springer-Verlag, 1997.
13. Chapuis PH, Dent OF, Fisher R et al: A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 72: 698-702, 1985.
14. Hermanek P: Problems of pTNM classification of carcinoma of the stomach, colorectum and anal margin. Pathol Res Pract 181: 296-300, 1986.
15. Wichman MW, Müller C, Hornung HM et al: Gender differences in long-term survival of patients with colorectal cancer. Br J Surg 88: 1092-1098, 2001.
16. Wolmark N, Wieand HS, Shibata H et al: The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg 198: 743-752, 1983.
17. Muto T, Kotake K and Koyama Y: Colorectal cancer statistics in Japan: data from JSCCR registration, 1974-1993. Int J Clin Oncol 6: 171-176, 2001.
18. Compton CC, Fielding LP, Burgart LJ et al: Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 979-994, 2000.
19. Minsky BD, Mies C, Chaffey JT et al: Resectable adenocarcinoma of the rectosigmoid and rectum. I. Patterns of failure and survival. Cancer 61: 1408-1416, 1988.
20. Tepper JE, O'Connell MJ, Mayer RJ et al: Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 19: 157-163, 2001.
21. Prandi M, Lionetto R, Rosso R et al: Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 235: 458-463, 2002.
22. Michelassi F, Vannucci L, Block GE et al: Local recurrence after curative resection of colorectal adenocarcinoma. Surgery 108: 787-792, 1990.
23. Pfannschmidt J, Muley T, Hoffmann H and Dienemann H: Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. J Thorac Cardiovasc Surg 126: 732-739, 2003.
24. Jaeck D, Oussoultzoglou E, Rosso E et al: A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 240: 1037-1051, 2004.
25. Chau I, Chan S and Cunningham D: Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives. Clin Colored Cancer 3: 19-33, 2003.
26. Kemeny N, Huang Y, Cohen AM et al: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 341: 2039-2048, 1999.
27. Lorenz M, Muller HH, Schramm H et al: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 228: 756-762, 1998.
28. Martin JK Jr, O'Connell MJ, Wieand HS et al: Intra-arterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer: a randomized trial. Arch Surg 125: 1022-1027, 1990.
29. Scheithauer W, Kornek G, Marczell A et al: Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. J Clin Oncol 15: 908-914, 1997.
30. Goldberg RM, Hatfield AK, Kahn M et al: Prospectively randomized North Central Cancer Treatment Group Trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. J Clin Oncol 15: 3320-3329, 1997.
31. Saltz LB, Cox JV, Blanke C et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905-914, 2000.
32. Douillard JY, Cunningham D, Roth AD et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 355: 1041-1047, 2000.
33. Kemeny N, Israel K, Niedzwiecki D et al: Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J Clin Oncol 8: 313-318, 1990.
34. Kato T, Ohashi Y, Nakazato H et al: Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbeck's Arch Surg 386: 575-581, 2002.
35. Maindrault-Goebel F, Louvet C, André T et al: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Cancer 35: 1338-1342, 1999.
36. De Gramont A, Vignoud J, Tournigand C et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214-219, 1997.
37. André T, Bensmaine MA, Louvet C et al: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17: 3560-3568, 1999.
38. Maindrault-Goebel F, de Gramont A, Louvet C et al: High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX7). Eur J Cancer 37: 1000-1005, 2001.
39. Cunningham D, Humblet Y, Siena S et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004.
40. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65, 2003.
41. Cutsem EV, Hoff PM, Harper P et al: Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 90: 1190-1197, 2004.
42. Cassidy J, Tabernero J, Twelves C et al: XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084-2091, 2004.
43. Kimura H, Konishi K, Nukui T et al: Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma. J Surg Oncol 76: 31-36, 2001.